Clinical trials: Acute Phase
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
This was a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS.
- Trial name
- NCT03940352
- Testing
- HDM201, MBG453, Venetoclax
- Where
- 9 sites in United States, Australia and 5 more
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
- Trial name
- NCT00144963
- Testing
- Vincristine Sulfate Liposomes Injection, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Acrotech Biopharma Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed.
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT01926587
- Testing
- oral rigosertib, Azacitidine
- Where
- 13 sites in United States, France
- Volunteers
- 45 people
- Sponsor
- Traws Pharma, Inc.
Acute Hepatic Porphyria, Acute Intermittent Porphyria
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).
- Conditions
- Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria
- Trial name
- NCT03338816
- Testing
- Givosiran
- Where
- 36 sites in United States, Australia and 16 more
- Volunteers
- 94 people
- Sponsor
- Alnylam Pharmaceuticals
Ulcerative Colitis
A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
This is a multicenter, placebo-controlled, parallel-group, pilot study to evaluate safety and preliminary effectiveness of two blinded dose levels of telotristat etiprate (LX1606) in participants with acute, mild to moderate…
- Trial name
- NCT01456052
- Testing
- Telotristat Etiprate
- Where
- 24 sites in United States, Lithuania and 2 more
- Volunteers
- 59 people
- Sponsor
- Lexicon Pharmaceuticals
Hematologic Malignancies
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
The purpose of this study is to evaluate the efficacy of TXA127 to reduce the incidence (Grade II-IV) of acute Graft-vs.-Host Disease (aGVHD) in adult subjects undergoing allogeneic peripheral blood stem cell transplantation…
- Trial name
- NCT01882387
- Testing
- TXA127
- Where
- 2 sites in United States
- Sponsor
- Tarix Pharmaceuticals
Migraine
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
The purpose of this study to show that zavegepant 10 milligrams given through the nose provides: freedom from pain, 2 hours after taking the medicine for the first migraine attack.
- Trial name
- NCT06103734
- Testing
- Zavegepant 10 mg
- Sponsor
- Pfizer
Spinal Cord Injury
Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries
Autologous Incubated Macrophages (ProCord) is being developed as a therapy for acute, complete spinal cord injury (SCI). The therapy is intended to reverse the loss of motor and sensory function.
- Trial name
- NCT00073853
- Testing
- Autologous Incubated Macrophages (cell therapy)
- Where
- 7 sites in United States, Israel
- Volunteers
- 61 people
- Sponsor
- Proneuron Biotechnologies
Acute Liver Failure, Acute Liver Injury, Drug Induced
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure.
- Conditions
- Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
- Trial name
- NCT06285253
- Testing
- miroliverELAP treatment
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Miromatrix Medical Inc.
Adjunct in the Treatment of Depressive Disorder
A Randomized, Open-Label, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study
This multicenter, randomized, open-label extension study will evaluate the maintenance of remission, relapse prevention, long-term clinical outcomes, and safety of CreNeuroS™ in participants with Major Depressive Disorder (MDD)…
- Trial name
- NCT07893002
- Testing
- No intervention, CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsule orally once daily, CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsule orally once daily
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Sichuan Credit Pharmaceutical Co., Ltd.
Gastroenteritis
Bivalent Norovirus Vaccine Study
Randomized, multi-site, dose-escalation study of the safety and immunogenicity of four dosage levels of Intramuscular (IM) Norovirus Bivalent VLP Vaccine adjuvanted with MPL and Al(OH)3 compared to controls.
- Trial name
- NCT01168401
- Testing
- NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline
- Where
- 3 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Takeda
Myelodysplastic Syndromes, Acute Myeloid Leukemia
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
This study is to determine the safety and preliminary efficacy of sabatolimab in combination with magrolimab and azacitidine in adult participants with 1L unfit Acute Myeloid Leukemia (AML) or with 1L higher risk Myelodysplastic…
- Trial name
- NCT05367401
- Testing
- Sabatolimab, Magrolimab, Azacitidine
- Sponsor
- Novartis Pharmaceuticals
Musculoskeletal Pain, Acute Pain
Efficacy and Safety Study of Ibuprofen Gel Compared to Placebo in the Treatment of Acute Musculoskeletal Pain
Phase III clinical trial, multicentre of superiority, randomized, double-blind, parallel groups, placebo-controlled and use of ibuprofen gel in the treatment of acute pain.
- Conditions
- Musculoskeletal Pain, Acute Pain, Stretch, Sprains
- Trial name
- PROGEL (NCT05013567)
- Testing
- Ibuprofen gel
- Volunteers
- 300 people
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Acute Myeloid Leukemia
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
This Phase Ib study is designed to evaluate the safety and pharmacokinetics of atezolizumab when given in combination with Hu5F9-G4 to patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
- Trial name
- NCT03922477
- Testing
- Atezolizumab, Hu5F9-G4
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Acute Myocardial Infarction
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel)…
- Trial name
- PACIFIC-AMI (NCT04304534)
- Testing
- BAY2433334
- Where
- 160 sites in United States, Austria and 12 more
- Volunteers
- 1,601 people
- Sponsor
- Bayer
Acute Bronchiolitis Due to Respiratory Syncytial Virus
Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus
The primary and secondary objectives of this Phase 1 study are respectively to assess the safety and the immunogenicity of two administrations of the RSV vaccine candidate at three different doses.
- Trial name
- NCT04519073
- Testing
- V-306 candidate vaccine
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Virometix
Acute Myeloid Leukemia
Single Dose Study With 4SC-203 in Healthy Volunteers
The purpose of the study is to evaluate safety and tolerability of 4SC-203 after a single dose administration in healthy volunteers.
- Trial name
- NCT01054937
- Testing
- 4SC-203
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- 4SC AG
Ionizing Radiation Exposure
Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)
The objective of the study is to evaluate the safety of intramuscular (IM) administration of PLX-R18 in subjects exposed to ionizing radiation and who are at risk of developing HS-ARS.
- Trial name
- HS-ARS (NCT03797040)
- Testing
- Cell therapy
- Volunteers
- 27 people
- Sponsor
- Pluristem Ltd.
Lymphoma, Acute Lymphocytic Leukemia
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
This is an open-label, dose-escalation Phase 1 study of the investigational agent, ON 013105. In laboratory animal studies, ON 013105 has demonstrated anti-cancer activity.
- Trial name
- NCT01049113
- Testing
- ON 013105
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Traws Pharma, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation…
- Trial name
- NCT03250338
- Testing
- Crenolanib, Cytarabine, Mitoxantrone
- Where
- 62 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- Arog Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.